A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin
暂无分享,去创建一个
Shou-Dong Lee | Chung‐Chi Lin | Yuan‐Jen Wang | C. Chu | Yi‐Hsiang Huang | M. Hou | F. Lee | C. Su | Sih-Hsien Wu
[1] Ding‐Shinn Chen,et al. Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan , 2018, Journal of Gastroenterology and Hepatology.
[2] G. Dore,et al. Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study , 2017, Antiviral therapy.
[3] V. Wong,et al. Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong , 2017, Journal of gastroenterology and hepatology.
[4] F. Jorquera,et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. , 2017, Journal of hepatology.
[5] F. Jorquera,et al. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection , 2017, Journal of viral hepatitis.
[6] K. Simon,et al. Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study , 2016, Alimentary pharmacology & therapeutics.
[7] G. Ioannou,et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. , 2016, Gastroenterology.
[8] P. Belperio,et al. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice , 2016, Alimentary pharmacology & therapeutics.
[9] D. Bernstein,et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. , 2016, Journal of hepatology.
[10] J. Kao. Hepatitis C virus infection in Taiwan: Past, present, and future. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.
[11] G. Cooke,et al. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Ding‐Shinn Chen,et al. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma , 2015, Scientific Reports.
[13] J. Hoofnagle,et al. From non-A, non-B hepatitis to hepatitis C virus cure. , 2015, Journal of hepatology.
[14] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[15] O. Weiland,et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.
[16] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[17] R. Marinho,et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.
[18] Eoin Coakley,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[19] Thomas Berg,et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. , 2014, Gastroenterology.
[20] John McNally,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.
[21] L. Nguyen,et al. Systematic review: Asian patients with chronic hepatitis C infection , 2013, Alimentary pharmacology & therapeutics.
[22] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[23] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[24] A. Aghemo,et al. Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir , 2012, Biologics : targets & therapy.
[25] F. Sanai,et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[26] O. Weiland,et al. Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.
[27] L. Gravitz. Introduction: A smouldering public-health crisis , 2011, Nature.
[28] Stefan Zeuzem,et al. Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[29] Ming‐Lung Yu,et al. Treatment of chronic hepatitis C in Asia: When East meets West , 2009, Journal of gastroenterology and hepatology.
[30] Ding‐Shinn Chen,et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] Laurent Castera,et al. Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.
[32] N. Hayashi,et al. Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients , 2007, Journal of gastroenterology and hepatology.
[33] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[34] Stefan Zeuzem,et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.